Acrivon Therapeutics | 8-K: Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Acrivon Therapeutics | DEFA14A: Others
Acrivon Therapeutics | DEF 14A: Definitive information statements
Acrivon Therapeutics | 8-K: Current report
Acrivon Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Acrivon Therapeutics | 8-K: Current report
Acrivon Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Acrivon Therapeutics | 8-K: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Acrivon Therapeutics | 8-K: Current report
Acrivon Therapeutics | 8-K: Current report
Acrivon Therapeutics | 8-K: Current report
Acrivon Therapeutics | 8-K: Current report
Acrivon Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Acrivon Therapeutics | 8-K: Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
Acrivon Therapeutics | 8-K: Current report
Acrivon Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Acrivon Therapeutics | 8-K: Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
Acrivon Therapeutics | 8-K: Current report
Acrivon Therapeutics | 8-K: Current report
Acrivon Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations
No Data